10x Genomics Launches Next Generation Immune Profiling Product to Combat COVID-19
The new Chromium Single Cell Immune Profiling v2 product provides a comprehensive approach to simultaneously examine cellular heterogeneity of the immune system, T and B cell repertoire diversity, and antigen specificity at single cell resolution. Researchers can profile thousands of genes and hundreds of cell surface proteins, cell by cell and at scale, with enhanced sensitivity, resolution, and sequencing quality. The latest product offers up to a 60 percent increase in gene detection sensitivity, allowing users greater flexibility in reducing sequencing costs without a loss in gene diversity or accessing rare gene transcripts without an increase in cost.
Using the Chromium Single Cell Immune Profiling v2 product, researchers can:
- Characterize adaptive and innate immune cell diversity
- Identify and characterize rare cell types and biomarkers
- Analyze tissue microenvironment, disease progression, and drug immune response
- Perform large-scale antibody and TCR discovery for novel antigens
- Characterize immune responses to infection by measuring clonal expansions and immune cell phenotypes
- Focus on relevant genes and pathways with predesigned gene expression panels for immunology, oncology, and drug discovery, or design a fully custom panel
“With the number of coronavirus cases expected to reach 100,000 a day in the US alone, it is critical that we get the right products into the hands of scientists as soon as possible,” said
Over a dozen peer-reviewed papers have been published that feature the use of 10x Genomics Chromium Single Cell Immune Profiling product in COVID-19 research, including studies to better understand the precise cells in which organs and tissues could become infected (Nature Medicine); immune system responses to COVID-19 infection across patients with varying severities of disease (Nature Cell Discovery, Nature Medicine); and ways neutralizing antibodies could be used to effectively block virus entry into host cells (Cell).
The Chromium Single Cell Immune Profiling v2 product is available for pre-order today and is expected to ship at the end of the month.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology. These forward-looking statements include statements regarding
Source: 10x Genomics, Inc.